Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (291-300 of 350) with videos related to

Pageof 35
Sort By:
Alimentary Pharmacology & Therapeutics|August 28, 2024
No value of non-selective beta-blockers after TIPS-insertionAnja Tiede, Lena Stockhoff, Hannah Rieland, et al.
Journal of Hepatology|January 18, 2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CMichael Manns, Stefan Zeuzem, Ajit Sood, et al.
Ebiomedicine|July 11, 2020
Reappearance of effector T cells is associated with recovery from COVID-19Ivan Odak, Joana Barros-Martins, Berislav Bošnjak, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 20, 2020
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II studyBirgit Bremer, Olympia E Anastasiou, Svenja Hardtke, et al.
Plos One|October 11, 2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAABenjamin Heidrich, Steffen B Wiegand, Peter Buggisch, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 18, 2024
Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International NetworkAnika Wranke, Cirley Lobato, Emanoil Ceausu, et al.
Journal of Hepatology|July 25, 2017
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE studyThomas Berg, Karl-Georg Simon, Stefan Mauss, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Journal of Medical Virology|August 21, 2008
Prevalence of HBV genotypes in Central and Eastern EuropeKatja Deterding, Ileana Constantinescu, Filofteia Daniela Nedelcu, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 30, 2009
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipientsSven Pischke, Pothakamuri V Suneetha, Christine Baechlein, et al.
Pageof 35

Showing results (291-300 of 350) with videos related to

Sort By:
Pageof 35
Alimentary Pharmacology & Therapeutics|August 28, 2024
No value of non-selective beta-blockers after TIPS-insertionAnja Tiede, Lena Stockhoff, Hannah Rieland, et al.
Journal of Hepatology|January 18, 2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CMichael Manns, Stefan Zeuzem, Ajit Sood, et al.
Ebiomedicine|July 11, 2020
Reappearance of effector T cells is associated with recovery from COVID-19Ivan Odak, Joana Barros-Martins, Berislav Bošnjak, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 20, 2020
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II studyBirgit Bremer, Olympia E Anastasiou, Svenja Hardtke, et al.
Plos One|October 11, 2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAABenjamin Heidrich, Steffen B Wiegand, Peter Buggisch, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 18, 2024
Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International NetworkAnika Wranke, Cirley Lobato, Emanoil Ceausu, et al.
Journal of Hepatology|July 25, 2017
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE studyThomas Berg, Karl-Georg Simon, Stefan Mauss, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Journal of Medical Virology|August 21, 2008
Prevalence of HBV genotypes in Central and Eastern EuropeKatja Deterding, Ileana Constantinescu, Filofteia Daniela Nedelcu, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 30, 2009
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipientsSven Pischke, Pothakamuri V Suneetha, Christine Baechlein, et al.
Pageof 35